【摘要】 目的 观察血管紧张素II受体拮抗剂代文 (Diovan,化学成分 :缬沙坦 )对轻、中度原发性高血压患者的降压疗效及安全性。方法 门诊选取轻、中度原发性高血压患者73例 ,服用代文胶囊80mg,或加服双氢克尿噻片12.5mg/25mg,1次/d ,测定服药前及服药后2、4、6、8周时的诊所坐位血压和心率 ,并测定服药前和服药8周后的立位血压、尿蛋白、尿糖、血肌酐、血电解质。结果 单用代文或加用双氢克尿噻后8周 ,坐位血压下降总有效率为77.78% ,其中显效47.22 % ,血压由服药前 (156.43±10.46/95.76±3.79)mmHg下降为 (134.56±9.15/82.38±6.01)mmHg,血压下降差别有显著性意义 (t=19.020,18.983 ,P<0.001) ;立位血压由服药前 (154.54±11.06/94.37±4.67)mmHg下降为 (133.75±9.40/81.76±6.00)mmHg,血压下降差别有显著性意义 (t=16.584,17.169,P<0.001) ,但未见直立性低血压发生 ;用药前后心率、尿糖、血肌酐及血电解质无明显改变 ,尿蛋白有减少。 结论 代文 ,作为血管紧张素II受体拮抗剂 ,用于治疗轻、中度原发性高血压患者 ,既安全又有效。更多还原

【Abstract】 Objective To investigate the efficacy and safety of valsartan in treatment of essential hyˉpertensive patients.Methods Seventy three patients with essential hypertension received valsartan80mg daily for8weeks;for some non-responded patients hydrochlorothiazide(12.5mg/25mg daily)was added.Results Valsartan reduced sitting blood pressure from(156.43±10.46)/(95.76±3.79)mmHg to(134.56±9.15)/(82.38±6.01)mmHg(t=19.020,18.983,P<0.001).Meanwhile standing blood pressure was reduced from(154.54±11.06)/(94.37±4.67)mmHg to(133.75±9.40)/(81.76±6.00)mmHg(t=16.584,17.169,P<0.001),and no patient had orthostatic hypotension caused by valsartan.The effective rate of valsartan was77.78%.Valsartan also reduced proteinuria.Conclusions In mild-moderate essential hypertensive patients,Valsartan was effective and well tolerated and offers a promising approach to the treatment of hypertension.更多还原